Longeveron is compressing every ten shares into one for the second time in roughly two and a half years. The move can lift the quoted share price above Nasdaq’s threshold. It does not put new cash in the bank or change the underlying value of the company.
According to the company’s August 2026 SEC filing, the 1-for-10 reverse split becomes effective at 11:59 p.m. on August 26, with split-adjusted trading expected to begin August 27 under the same LGVN symbol.
What changes on paper
About 30.43 million Class A shares will become roughly 3.04 million. About 1.45 million Class B shares will become approximately 144,901. Options, warrants and other equity awards will be adjusted proportionally. A holder’s percentage ownership should be essentially unchanged apart from the treatment of fractional shares.
Imagine owning 1,000 shares at $0.50 each. Immediately after a 1-for-10 split, the position would be 100 shares at a theoretical $5 each. The position is worth the same $500 before market movement. A reverse split changes the unit, not the business.
Why the $1 line matters
Nasdaq generally requires a listed company’s closing bid price to remain at or above $1. A company that trades below that level for a sustained period can receive a deficiency notice and a compliance window. If the market price does not recover, a reverse split is a common way to lift it mechanically and reduce the immediate risk of delisting.
Longeveron did the same thing in March 2024, when another 1-for-10 reverse split was also tied to Nasdaq bid-price compliance. Two identical splits do not prove that its drug programs will fail. They do show that the first reset did not lead to a share price that remained safely above the threshold.
The operating context
Longeveron’s lead cell therapy, laromestrocel, is being developed across programs that include hypoplastic left heart syndrome, Alzheimer’s disease, pediatric dilated cardiomyopathy and aging-related frailty. Clinical results can still change the company’s prospects substantially.
For investors, however, clinical promise and financing capacity are separate questions. In its second-quarter 2026 update, Longeveron reported $10.1 million in cash at June 30, quarterly revenue of about $0.3 million and a net loss of $6.1 million. Management said existing cash was expected to fund operations into the fourth quarter of 2026 and that it intended to pursue additional financing, capital raises and non-dilutive funding.
The reverse split itself is not a financing and is not immediate dilution. But the company’s authorized share counts are not reduced by the same ratio. That leaves more room, relative to the new number of outstanding shares, for future issuances. If new shares are sold to raise cash, existing holders can be diluted.
What the second split says, and what it does not
- It says: the company is again using a mechanical price adjustment to address listing pressure.
- It says: cash runway and access to capital remain material alongside trial execution.
- It does not say: shareholders gain value merely because each share has a higher price.
- It does not say: laromestrocel’s clinical data are positive or negative.
Reverse splits can also reduce liquidity and are often followed by volatility. The post-split price is set by arithmetic on day one, then by the market.
Bottom line: Longeveron’s second 1-for-10 reverse split is best read as a listing and capital-structure event. The decisive questions remain whether its trials generate persuasive results and whether it can finance the work on acceptable terms. This article explains the transaction and is not investment advice.
Sources: August 2026 Form 8-K; March 2024 reverse split announcement; Q2 2026 results